The stock may react positively to the CAPTN-3 platform's preclinical data and extended cash runway, but traders should monitor for partnership developments on discontinued assets and upcoming clinical trial initiations for IM1240. The lack of revenue and continued losses remain key risks.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $4.10entry
- T+1 · 8mo ago −0.24%α −1.27% · $4.09
- T+5 · 8mo ago −2.93%α −0.81% · $3.98
- T+20 · 7mo ago +0.73%α −2.86% · $4.13
- T+60 · 5mo ago −28.78%α −40.40% · $2.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge related to the discontinuation of CM24 and NT219 programs. However, the company highlighted progress in its CAPTN-3 platform, including preclinical success and a $9.5 million cash position providing runway into 2027. Despite strong R&D advancements, the substantial loss and program discontinuations weigh on near-term fundamentals.
Key Financial Metrics
Key Facts
- Reported net loss of $26.4 million for 2025, up from $7.2 million in 2024, primarily due to a $20.5 million impairment charge on CM24 and NT219 programs
- Cash and cash equivalents totaled $9.5 million as of December 31, 2025, expected to fund operations into 2027
- Achieved key preclinical milestones for IM1240 and IM1305, including toxicology and manufacturing success, with data showing multi-arm anti-tumor activity
- R&D expenses decreased to $3.7 million in 2025 from $7.6 million in 2024 due to reduced clinical trial costs, despite increased CMC activities
- Company will not advance CM24 and NT219 without a strategic partner or additional financing
Financial Impact
Impairment charge of $20.5 million significantly increased net loss; R&D spending cut in half year-over-year excluding non-cash items
Risk Factors
- Dependence on future financing or partnerships to advance legacy programs CM24 and NT219
- High cash burn relative to market cap; any delay in CAPTN-3 development could pressure liquidity
- Preclinical data may not translate into clinical success; no near-term revenue catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255440 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers